IGC-505

**IGC-505** is an investigational cannabinoid-based therapy attributed to IGC Pharma and publicly described as a proposed treatment for seizures in dogs and cats. Contemporary company-related reports characterized IGC-505 as one of two patent-filed cannabinoid combination therapies for veterinary seizures; however, the exact active ingredients, molecular targets, formulation, route of administration, and current development activity have not been publicly identified in sufficiently specific primary-source materials. A drug-development database has listed the program as preclinical for seizures, while IGC Pharma's current public pipeline does not list IGC-505. ([networknewswire.com](https://www.networknewswire.com/india-globalization-capital-inc-nyse-igc-plans-develop-cannabinoid-extract-therapies-cats-dogs/))